Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5)-Reference-Cited by-同舟云学术

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5)

Published:2019-06-04 Issue:5 Volume:11 Page:956-964
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Ahlberg Jennifer¹^ORCID,Giragossian Craig¹,Li Hua¹,Myzithras Maria¹,Raymond Ernie¹,Caviness Gary¹,Grimaldi Christine¹,Brown Su-Ellen¹,Perez Rocio¹,Yang Danlin¹^ORCID,Kroe-Barrett Rachel¹^ORCID,Joseph David¹,Pamulapati Chandrasena¹,Coble Kelly¹,Ruus Peter²,Woska Joseph R.¹,Ganesan Rajkumar¹^ORCID,Hansel Steven¹,Mbow M. Lamine¹

Affiliation:

1. Biotherapeutics Disccovery Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

2. Translational Medicine, Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rein, Germany

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/19420862.2019.1615345

Reference37 articles.

1. Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36α, IL-36β, and IL-36γ) or Antagonist (IL-36Ra) Activity

2. IL-36 in psoriasis